Tarsa Pads Coffers Ahead of NDA Filing for Oral Calcitonin
By Jennifer Boggs
Wednesday, July 13, 2011
Three months after reporting positive top-line data from its Phase III study of oral calcitonin in postmenopausal osteoporosis patients, Tarsa Therapeutics Inc. disclosed a $24.5 million financing round that should get the Philadelphia-based firm through a new drug application (NDA) filing later this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.